Vital Therapies to Present at the 19th International Liver Support Meeting
29 Setembro 2018 - 11:00AM
Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company that
has been developing ELAD®, a cell-based therapy targeting the
treatment of liver failure, today announced that additional data
from its VTL-308 clinical trial will be presented today at the 19th
International Liver Support Meeting in Rostock-Warnemunde,
Germany. The presentation, titled "Update on ELAD Study
VTL-308", will be made by Nikolaos T. Pyrsopoulos, M.D., Ph.D.,
Professor and Chief, Division of Gastroenterology and Hepatology,
Rutgers New Jersey Medical School.
Slides from the presentation will be available
on our website http://vitaltherapies.com in the "Research and
Clinical Development" section.
Investor Contact: Vital Therapies, Inc. Investor Relations
858-673-6840InvestorRelations@vitaltherapies.com
VITAL THERAPIES INC (NASDAQ:VTL)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
VITAL THERAPIES INC (NASDAQ:VTL)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Vital Therapies, Inc. (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de